tiprankstipranks
Advertisement
Advertisement

BMRN Stock Latest News

3 Best Stocks to Buy This Week, According to Analysts – May 25-May 29
Market News3 Best Stocks to Buy This Week, According to Analysts – May 25-May 29
1d ago
BMRN
FUTU
BioMarin price target lowered to $111 from $116 at Canaccord
PremiumThe Fly
BioMarin price target lowered to $111 from $116 at Canaccord
4d ago
BMRN
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
5d ago
BMRN
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
PremiumThe Fly
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
6d ago
BMRN
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
PremiumThe Fly
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
7d ago
AMT
BAP
BioMarin price target lowered to $80 from $85 at BofA
PremiumThe FlyBioMarin price target lowered to $80 from $85 at BofA
7d ago
BMRN
BioMarin initiated with a Buy at Citi
Premium
The Fly
BioMarin initiated with a Buy at Citi
8d ago
BMRN
BioMarin price target lowered to $62 from $64 at Leerink
Premium
The Fly
BioMarin price target lowered to $62 from $64 at Leerink
8d ago
BMRN
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
PremiumThe Fly
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
8d ago
BMRN
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
PremiumThe Fly
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
8d ago
BMRN
Morgan Stanley Sees the S&P 500 Hitting 8,300 – 2 Stocks It Says Could Surge Alongside It
PremiumMarket News
Morgan Stanley Sees the S&P 500 Hitting 8,300 – 2 Stocks It Says Could Surge Alongside It
11d ago
ARXS
BMRN
BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors
PremiumCompany Announcements
BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors
12d ago
BMRN
Dell downgraded, Uber upgraded: Wall Street’s top analyst calls
PremiumThe FlyDell downgraded, Uber upgraded: Wall Street’s top analyst calls
15d ago
CG
FTV
BioMarin reinstated with a Neutral at Goldman Sachs
Premium
The Fly
BioMarin reinstated with a Neutral at Goldman Sachs
15d ago
BMRN
BioMarin price target raised to $116 from $104 at Canaccord
Premium
The Fly
BioMarin price target raised to $116 from $104 at Canaccord
19d ago
BMRN
BioMarin price target lowered to $119 from $120 at Morgan Stanley
PremiumThe Fly
BioMarin price target lowered to $119 from $120 at Morgan Stanley
21d ago
BMRN
BioMarin price target raised to $120 from $110 at Evercore ISI
PremiumThe Fly
BioMarin price target raised to $120 from $110 at Evercore ISI
21d ago
BMRN
BioMarin price target lowered to $82 from $94 at Bernstein
PremiumThe Fly
BioMarin price target lowered to $82 from $94 at Bernstein
21d ago
BMRN
BioMarin: Buy Rating Reiterated on Amicus Acquisition Upside and Pipeline Catalysts; $85 Price Target Unchanged
PremiumRatings
BioMarin: Buy Rating Reiterated on Amicus Acquisition Upside and Pipeline Catalysts; $85 Price Target Unchanged
21d ago
BMRN
BioMarin Buy Rating Reiterated on Amicus Acquisition Synergies and Long-Term Upside; $120 Price Target Unchanged
PremiumRatingsBioMarin Buy Rating Reiterated on Amicus Acquisition Synergies and Long-Term Upside; $120 Price Target Unchanged
22d ago
BMRN
BioMarin Boosts 2026 Outlook After Amicus Deal
Premium
Company Announcements
BioMarin Boosts 2026 Outlook After Amicus Deal
22d ago
BMRN
BioMarin lowers FY26 non-GAAP EPS view to $4.85-$5.05 from $4.95-$5.15
Premium
The Fly
BioMarin lowers FY26 non-GAAP EPS view to $4.85-$5.05 from $4.95-$5.15
22d ago
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >